Skip to main content
SpringerLink
Log in

Epidermolysis Bullosa Acquisita

  • Chapter
  • First Online:
Diseases of the Oral Mucosa

  • 1709 Accesses

Abstract

Epidermolysis bullosa acquisita (EBA) is an orphan autoimmune blistering disease. Blistering and increased skin fragility can occur at any site of the body with squamous epithelia, i.e. the oral mucosa and/or skin. Through so far unknown mechanisms, tolerance against type VII collagen (Col7) is lost. Subsequently, plasma cells produce autoantibodies directed against Col7. After autoantibody binding, tissue pathology is induced by an inflammatory response that is triggered by the deposited immune complexes. Alternatively, subepidermal blistering can also be induced by so far unknown mechanisms in the absence of inflammation. Accordingly, two different clinical presentations are observed: In inflammatory (or non-mechano-bullous) EBA, tense blisters and/or erosions are found at inflamed skin. Mechano-bullous, also termed classical EBA, presents with skin fragility, blisters, or erosions on non-inflamed skin, leading to subsequent scarring and milia formation. Independent of the clinical presentation, EBA may be complicated by mucous membrane involvement, most often affecting the oral mucosa. Diagnosis is confirmed by the presence of linear immunoglobulin or complement deposits along the dermal-epidermal junction in a perilesional skin or mucosal biopsy and detection of (1) a specific binding pattern of the Ig-deposits, or (2) circulating anti-Col7 antibodies in the serum. Overall, EBA is notoriously difficult to treat. Treatment is based on generalized immunosuppression. Metanalysis of over 1000 EBA cases indicated that either high dose intravenous immunoglobulin or the anti-CD20 antibody rituximab may be best suited to induce remissions. This chapter gives a detailed overview about the disease and its management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Elliott G. Two cases of epidermolysis bullosa. J Cutan Genitourin Dis. 1895;13:10.

    Google Scholar 

  2. Hübner F, Recke A, Zillikens D, Linder R, Schmidt E. Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J Invest Dermatol. 2016;136(12):2495–8.

    Article  Google Scholar 

  3. Bertram F, Bröcker E-B, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in lower Franconia. Germany J Dtsch Dermatol Ges. 2009;7(5):434–40.

    PubMed  Google Scholar 

  4. Milinković MV, Janković S, Medenica L, Nikolić M, Reljić V, Popadić S, et al. Incidence of autoimmune bullous diseases in Serbia: a 20-year retrospective study. J Dtsch Dermatol Ges. 2016;14(10):995–1005.

    Google Scholar 

  5. Iwata H, Vorobyev A, Koga H, Recke A, Zillikens D, Prost-Squarcioni C, et al. Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients. Orphanet J Rare Dis. 2018;13(1):1–9.

    Article  Google Scholar 

  6. Noe M, Chen M, Woodley D, Fairley J. Familial epidermolysis bullosa acquisita. Dermatol Online J. 2008;14(12):2.

    Article  Google Scholar 

  7. Kasperkiewicz M, Sadik CD, Bieber K, Ibrahim SM, Manz RA, Schmidt E, et al. Epidermolysis bullosa Acquisita: from pathophysiology to novel therapeutic options. J Invest Dermatol. 2016;136(1):24–33.

    Article  CAS  Google Scholar 

  8. Zumelzu C, Le Roux-Villet C, Loiseau P, Busson M, Heller M, Aucouturier F, et al. Black patients of African descent and HLA-DRB1*15:03 frequency overrepresented in epidermolysis bullosa Acquisita. J Invest Dermatol. 2011;131(12):2386–93.

    Article  CAS  Google Scholar 

  9. Gammon WR, Heise ER, Burke WA, Fine JD, Woodley DT, Briggaman RA. Increased frequency of HLA-DR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen: evidence that the expression of autoimmunity to type VII collagen is HLA class II allele associated. J Invest Dermatol. 1988;91:228–32.

    Article  CAS  Google Scholar 

  10. Prost-Squarcioni C, Caux F, Schmidt E, Jonkman MF, Vassileva S, Kim SC, et al. International bullous diseases group: consensus on diagnostic criteria for epidermolysis bullosa acquisita. Br J Dermatol. 2018;179(1):30–41.

    Article  CAS  Google Scholar 

  11. Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, et al. The first international consensus on mucous membrane pemphigoid. Arch Dermatol. 2002 Mar 1;138(3):370–9.

    Article  Google Scholar 

  12. Terra JB, Meijer JM, Jonkman MF, Diercks GFH. The n- vs. u-serration is a learnable criterion to differentiate pemphigoid from epidermolysis bullosa acquisita in direct immunofluorescence serration pattern analysis. Br J Dermatol. 2013;169(1):100–5.

    Article  CAS  Google Scholar 

  13. Holtsche M, van Beek N, Künstner A, Busch H, Zillikens D, Schmidt E. Diagnostic value and practicability of serration pattern analysis by direct immunofluorescence microscopy in pemphigoid diseases. Acta Derm Venereol. 2021;101(3):adv00410.

    Google Scholar 

  14. Vorobyev A, Ludwig RJ, Schmidt E. Clinical features and diagnosis of epidermolysis bullosa acquisita. Expert Rev Clin Immunol. 2017;13(2):157–69.

    Article  CAS  Google Scholar 

  15. Komorowski L, Müller R, Vorobyev A, Probst C, Recke A, Jonkman MF, et al. Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita. J Am Acad Dermatol. 2013;68(3):89–95.

    Article  Google Scholar 

  16. Kasprick A, Bieber K, Ludwig RJ. Drug discovery for pemphigoid diseases. Curr Protoc Pharmacol. 2019;84(1):1–26.

    Article  Google Scholar 

  17. Woodley DT, Briggaman RA, O’Keefe EJ, Inman AO, Queen LL, Gammon WR. Identification of the skin basement-membrane autoantigen in epidermolysis bullosa Acquisita. N Engl J Med. 1984;310(16):1007–13.

    Google Scholar 

  18. Vorobyev A, Ujiie H, Recke A, Buijsrogge JJA, Jonkman MF, Pas HH, et al. Autoantibodies to multiple epitopes on the non-Collagenous-1 domain of type VII collagen induce blisters. J Invest Dermatol. 2015;135(6):1565–73.

    Google Scholar 

  19. Koga H, Prost-Squarcioni C, Iwata H, Jonkman MF, Ludwig RJ, Bieber K. Epidermolysis Bullosa Acquisita: the 2019 update. Front Med. 2019;5 (1):362.

    Google Scholar 

  20. Iwata H, Bieber K, Tiburzy B, Chrobok N, Kalies K, Shimizu A, et al. B cells, dendritic cells, and macrophages are required to induce an autoreactive CD4 helper T cell response in experimental epidermolysis bullosa Acquisita. J Immunol. 2013;191(6):2978–88.

    Article  CAS  Google Scholar 

  21. Sitaru AG, Sesarman A, Mihai S, Chiriac MT, Zillikens D, Hultman P, et al. T cells are required for the production of blister-inducing autoantibodies in experimental epidermolysis bullosa Acquisita. J Immunol. 2010;184(3):1596–603.

    Article  CAS  Google Scholar 

  22. Samavedam UKSRL, Iwata H, Muller S, Schulze FS, Recke A, Schmidt E, et al. GM-CSF modulates autoantibody production and skin blistering in experimental epidermolysis bullosa Acquisita. J Immunol. 2014;192(2):559–71.

    Article  CAS  Google Scholar 

  23. Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, et al. Anti-inflammatory activity of IgG1 mediated by fc galactosylation and association of FcγRIIB and dectin-1. Nat Med. 2012;18(9):1401–6.

    Article  CAS  Google Scholar 

  24. Kasprick A, Hofrichter M, Smith B, Ward P, Bieber K, Shock A, et al. Treatment with anti-neonatal fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice. Br J Pharmacol. 2020;177(10):2381–92.

    Article  CAS  Google Scholar 

  25. Ludwig RJ, Vanhoorelbeke K, Leypoldt F, Kaya Z, Bieber K, McLachlan SM, et al. Mechanisms of autoantibody-induced pathology. Front Immunol. 2017;8:603.

    Article  Google Scholar 

  26. Patel PM, Jones VA, Murray TN, Amber KT. A Review comparing international guidelines for the Management of Bullous Pemphigoid, pemphigoid Gestationis, mucous membrane pemphigoid, and epidermolysis bullosa Acquisita. Am J Clin Dermatol. 2020;21(4):557–65.

    Article  Google Scholar 

  27. Bieber K, Ludwig RJ. Drug development in pemphigoid diseases. Acta Derm Venereol. 2020;100(5):adv00055.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Lübeck, Lübeck, Germany

    Sören Dräger & Ralf J. Ludwig

Authors
  1. Sören Dräger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ralf J. Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sören Dräger .

Editor information

Editors and Affiliations

  1. Lübeck Institute of Experimental Dermatology (LIED) and Department of Dermatology, University of Lübeck, Lübeck, Germany

    Enno Schmidt

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Dräger, S., Ludwig, R.J. (2021). Epidermolysis Bullosa Acquisita. In: Schmidt, E. (eds) Diseases of the Oral Mucosa. Springer, Cham. https://doi.org/10.1007/978-3-030-82804-2_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-82804-2_24

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-82803-5

  • Online ISBN: 978-3-030-82804-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation